JP2018520650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520650A5 JP2018520650A5 JP2017560535A JP2017560535A JP2018520650A5 JP 2018520650 A5 JP2018520650 A5 JP 2018520650A5 JP 2017560535 A JP2017560535 A JP 2017560535A JP 2017560535 A JP2017560535 A JP 2017560535A JP 2018520650 A5 JP2018520650 A5 JP 2018520650A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cancer
- specific
- bispecific
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022077013A JP7419434B2 (ja) | 2015-05-21 | 2022-05-09 | 新規のポリペプチド |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1508729.9 | 2015-05-21 | ||
| GBGB1508729.9A GB201508729D0 (en) | 2015-05-21 | 2015-05-21 | Binding molecules |
| GBGB1514994.1A GB201514994D0 (en) | 2015-08-24 | 2015-08-24 | Bispecific polypeptide |
| GB1514994.1 | 2015-08-24 | ||
| GB201605450 | 2016-03-31 | ||
| GB1605450.4 | 2016-03-31 | ||
| PCT/EP2016/061420 WO2016185016A1 (en) | 2015-05-21 | 2016-05-20 | Novel polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077013A Division JP7419434B2 (ja) | 2015-05-21 | 2022-05-09 | 新規のポリペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520650A JP2018520650A (ja) | 2018-08-02 |
| JP2018520650A5 true JP2018520650A5 (OSRAM) | 2019-06-20 |
Family
ID=56026872
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560535A Pending JP2018520650A (ja) | 2015-05-21 | 2016-05-20 | 新規のポリペプチド |
| JP2022077013A Active JP7419434B2 (ja) | 2015-05-21 | 2022-05-09 | 新規のポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077013A Active JP7419434B2 (ja) | 2015-05-21 | 2022-05-09 | 新規のポリペプチド |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11008396B2 (OSRAM) |
| EP (2) | EP3988577A1 (OSRAM) |
| JP (2) | JP2018520650A (OSRAM) |
| KR (1) | KR102712820B1 (OSRAM) |
| CN (2) | CN107709367A (OSRAM) |
| AU (1) | AU2016265447B2 (OSRAM) |
| BR (1) | BR112017024770A2 (OSRAM) |
| CA (1) | CA2986415A1 (OSRAM) |
| IL (1) | IL255767B2 (OSRAM) |
| MX (1) | MX2017014699A (OSRAM) |
| RU (1) | RU2017142008A (OSRAM) |
| WO (1) | WO2016185016A1 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3328408B1 (en) | 2015-07-31 | 2020-10-07 | Vascular Biogenics Ltd. | Motile sperm domain containing protein 2 and inflammation |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| KR102426765B1 (ko) * | 2016-04-22 | 2022-07-29 | 엘리게이터 바이오사이언스 에이비 | Cd137에 대한 신규한 이중특이성 폴리펩타이드 |
| US11214618B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | LAG-3 binding members |
| US11214620B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | Binding molecules binding PD-L1 and LAG-3 |
| GB201611530D0 (en) * | 2016-07-01 | 2016-08-17 | Alligator Bioscience Ab | Novel polypeptides |
| UA128304C2 (uk) | 2016-07-14 | 2024-06-05 | Ґенмаб А/С | Мультиспецифічне антитіло до cd40 і cd137 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| CN117510643A (zh) * | 2016-09-23 | 2024-02-06 | 美勒斯公司 | 调节细胞表达的生物活性的结合分子 |
| GB201619652D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel polypeptides |
| GB201619648D0 (en) * | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| KR20210157471A (ko) * | 2016-12-15 | 2021-12-28 | 애브비 바이오테라퓨틱스 인크. | 항-ox40 항체 및 이의 용도 |
| EP3585431A4 (en) * | 2017-02-24 | 2020-12-16 | MacroGenics, Inc. | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES |
| BR112019017241A2 (pt) | 2017-04-13 | 2020-04-14 | Agenus Inc | anticorpos anti-cd137 e métodos de uso dos mesmos |
| KR20200002889A (ko) * | 2017-05-02 | 2020-01-08 | 엘리게이터 바이오사이언스 에이비 | Ox40 및 ctla-4에 대한 이중특이적 항체 |
| MX2019013648A (es) | 2017-05-19 | 2021-01-08 | Wuxi Biologics Shanghai Co Ltd | Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4). |
| EP3641812A1 (en) * | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| EP3652209A2 (en) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonist antibodies that bind human cd137 and uses thereof |
| CA3070272A1 (en) | 2017-07-20 | 2019-01-24 | Aptevo Research And Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| CN111741976B (zh) | 2017-12-19 | 2024-09-17 | 英沃克斯制药有限公司 | 包括pd-l1抗原结合位点的fc结合片段 |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| CA3093633A1 (en) * | 2018-03-13 | 2019-09-19 | Vascular Biogenics Ltd. | Bispecific antibodies to mospd2 and t cell- or nk cell-specific molecules |
| CN110467674B (zh) * | 2018-05-11 | 2022-05-31 | 同润澳门一人有限公司 | 抗ox40的全人抗体及其制备方法和用途 |
| CA3106048A1 (en) * | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Antibody molecules that bind cd137 and ox40 |
| CN112423845B (zh) | 2018-07-12 | 2024-07-30 | F-星治疗有限公司 | 结合pd-l1和cd137的抗体分子 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| WO2020113164A1 (en) * | 2018-11-30 | 2020-06-04 | Memorial Sloan Kettering Cancer Center | Heterodimeric tetravalency and specificity antibody compositions and uses thereof |
| US20220064325A1 (en) * | 2018-12-17 | 2022-03-03 | Alligator Bioscience Ab | Novel polypeptides |
| BR112021012631A2 (pt) | 2018-12-26 | 2021-12-14 | Xilio Dev Inc | Anticorpos anti-ctla4 e métodos de uso dos mesmos |
| WO2020216947A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| US20220242962A1 (en) * | 2019-08-12 | 2022-08-04 | Aptevo Research And Development Llc | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
| EP4041772A4 (en) * | 2019-10-11 | 2024-04-24 | Nanjing Leads Biolabs Co., Ltd. | 4-1BB-BINDING ANTIBODIES AND USES THEREOF |
| CN113045655A (zh) * | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
| AU2021207470A1 (en) | 2020-01-13 | 2022-07-07 | Aptevo Research And Development Llc | Formulations for protein therapeutics |
| BR112022013730A2 (pt) | 2020-01-13 | 2022-10-11 | Aptevo Res & Development Llc | Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| CA3191242A1 (en) | 2020-09-10 | 2022-03-17 | Itzhak Mendel | Motile sperm domain containing protein 2 antibodies and methods of use thereof |
| US20240150483A1 (en) * | 2021-02-17 | 2024-05-09 | Aptevo Research And Development Llc | COMPOSITIONS COMPRISING 4-1BB and OX40 BINDING PROTEINS AND METHODS OF USE |
| WO2022246244A1 (en) | 2021-05-21 | 2022-11-24 | Aptevo Research And Development Llc | Dosing regimens for protein therapeutics |
| CN119110809A (zh) | 2022-02-23 | 2024-12-10 | Xencor股份有限公司 | 抗CD28 x抗PSMA抗体 |
| US12195546B2 (en) | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| AU2024237581A1 (en) * | 2023-03-14 | 2025-10-02 | Xencor, Inc. | Anti-cd28 compositions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| KR100452954B1 (ko) * | 2002-02-26 | 2004-10-14 | 주식회사 엘지생명과학 | 가변영역 아미노산 치환을 통한 인간 4-1비비분자에 대한결합 특이성이 증가된 변형 인간화 항체의 제조방법 |
| AU2004210088A1 (en) * | 2003-02-06 | 2004-08-19 | Micromet Ag | Trimeric polypeptide construct to induce an enduring T cell response |
| CN1894413A (zh) * | 2003-03-26 | 2007-01-10 | 特鲁比昂药品公司 | 识别cd3或4－1bb的抗体或基因介导的肿瘤反应性淋巴细胞活化 |
| AR046094A1 (es) * | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| US20070253961A1 (en) * | 2004-06-09 | 2007-11-01 | Ulsan Industrial Education Foundation | Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis |
| EP1851244A4 (en) | 2005-02-15 | 2009-04-15 | Gtc Biotherapeutics Inc | ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| SG186656A1 (en) * | 2007-12-14 | 2013-01-30 | Bristol Myers Squibb Co | Binding molecules to the human ox40 receptor |
| US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
| CN110066339A (zh) | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
| MX337040B (es) * | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| CA3019531A1 (en) * | 2011-04-19 | 2012-10-26 | Pfizer Inc. | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| BR112015005772A2 (pt) | 2012-09-17 | 2017-08-08 | Galectin Therapeutics Inc | método para a intensificação de imunoterapias específicas no tratamento de câncer |
| GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| MX2016007965A (es) * | 2013-12-17 | 2016-10-28 | Genentech Inc | Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1. |
| EP3258959A4 (en) * | 2015-02-22 | 2018-10-17 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd137 |
-
2016
- 2016-05-20 RU RU2017142008A patent/RU2017142008A/ru unknown
- 2016-05-20 CA CA2986415A patent/CA2986415A1/en active Pending
- 2016-05-20 JP JP2017560535A patent/JP2018520650A/ja active Pending
- 2016-05-20 EP EP21202262.8A patent/EP3988577A1/en active Pending
- 2016-05-20 CN CN201680028916.5A patent/CN107709367A/zh active Pending
- 2016-05-20 MX MX2017014699A patent/MX2017014699A/es unknown
- 2016-05-20 BR BR112017024770A patent/BR112017024770A2/pt not_active IP Right Cessation
- 2016-05-20 CN CN202111495490.3A patent/CN114181309B/zh active Active
- 2016-05-20 IL IL255767A patent/IL255767B2/en unknown
- 2016-05-20 AU AU2016265447A patent/AU2016265447B2/en active Active
- 2016-05-20 KR KR1020177033709A patent/KR102712820B1/ko active Active
- 2016-05-20 WO PCT/EP2016/061420 patent/WO2016185016A1/en not_active Ceased
- 2016-05-20 US US15/567,163 patent/US11008396B2/en not_active Expired - Fee Related
- 2016-05-20 EP EP16724036.5A patent/EP3298045A1/en not_active Withdrawn
-
2020
- 2020-02-03 US US16/780,401 patent/US10774150B2/en not_active Expired - Fee Related
-
2021
- 2021-04-13 US US17/229,130 patent/US11780928B2/en active Active
-
2022
- 2022-05-09 JP JP2022077013A patent/JP7419434B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520650A5 (OSRAM) | ||
| RU2017142008A (ru) | Новые полипептиды | |
| JP2016529215A5 (OSRAM) | ||
| JP2020501531A5 (OSRAM) | ||
| HRP20211333T1 (hr) | Molekule za vezanje pd-1 i lag-3 i postupci za njihovu uporabu | |
| JP2019500891A5 (OSRAM) | ||
| JP2019501883A5 (OSRAM) | ||
| JP2018503380A5 (OSRAM) | ||
| IL273424B2 (en) | Novel bispecific cd3/cd19 polypeptide complexes | |
| JP2019529373A5 (ja) | 抗Ｔｉｍ−３抗体 | |
| JP2018503365A5 (OSRAM) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2019500892A5 (OSRAM) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2010531140A5 (OSRAM) | ||
| RU2019138067A (ru) | Биспецифическое антитело против ox40 и ctla-4 | |
| JP2017506067A5 (OSRAM) | ||
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2016537966A5 (OSRAM) | ||
| JP2014158469A5 (OSRAM) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| JP2020502271A5 (OSRAM) | ||
| JP2013527761A5 (OSRAM) | ||
| JP2013519364A5 (OSRAM) | ||
| JP2016512223A5 (OSRAM) |